Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02334735Phase 2Completed

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Role: lead

NCT02721043Phase 1Completed

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Role: lead

NCT03241927Phase 2Terminated

Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)

Role: lead

NCT02071095Phase 1Completed

Enhancement by Poly-ICLC During HIV-1 Infection

Role: lead

NCT01079741Phase 1Completed

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Role: lead

NCT01984892Phase 2Terminated

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

Role: lead

NCT00821652Phase 1Completed

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

Role: lead

All 7 trials loaded